Literature DB >> 21575859

Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer.

Brett S Carver1, Caren Chapinski, John Wongvipat, Haley Hieronymus, Yu Chen, Sarat Chandarlapaty, Vivek K Arora, Carl Le, Jason Koutcher, Howard Scher, Peter T Scardino, Neal Rosen, Charles L Sawyers.   

Abstract

Prostate cancer is characterized by its dependence on androgen receptor (AR) and frequent activation of PI3K signaling. We find that AR transcriptional output is decreased in human and murine tumors with PTEN deletion and that PI3K pathway inhibition activates AR signaling by relieving feedback inhibition of HER kinases. Similarly, AR inhibition activates AKT signaling by reducing levels of the AKT phosphatase PHLPP. Thus, these two oncogenic pathways cross-regulate each other by reciprocal feedback. Inhibition of one activates the other, thereby maintaining tumor cell survival. However, combined pharmacologic inhibition of PI3K and AR signaling caused near-complete prostate cancer regressions in a Pten-deficient murine prostate cancer model and in human prostate cancer xenografts, indicating that both pathways coordinately support survival.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21575859      PMCID: PMC3142785          DOI: 10.1016/j.ccr.2011.04.008

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  45 in total

1.  Targeting HER2 in prostate cancer: where to next?

Authors:  David B Solit; Neal Rosen
Journal:  J Clin Oncol       Date:  2007-01-20       Impact factor: 44.544

2.  Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators.

Authors:  Haley Hieronymus; Justin Lamb; Kenneth N Ross; Xiao P Peng; Cristina Clement; Anna Rodina; Maria Nieto; Jinyan Du; Kimberly Stegmaier; Srilakshmi M Raj; Katherine N Maloney; Jon Clardy; William C Hahn; Gabriela Chiosis; Todd R Golub
Journal:  Cancer Cell       Date:  2006-09-28       Impact factor: 31.743

3.  PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth.

Authors:  Tianyan Gao; Frank Furnari; Alexandra C Newton
Journal:  Mol Cell       Date:  2005-04-01       Impact factor: 17.970

4.  Differential requirement of mTOR in postmitotic tissues and tumorigenesis.

Authors:  Caterina Nardella; Arkaitz Carracedo; Andrea Alimonti; Robin M Hobbs; John G Clohessy; Zhenbang Chen; Ainara Egia; Alessandro Fornari; Michelangelo Fiorentino; Massimo Loda; Sara C Kozma; George Thomas; Carlos Cordon-Cardo; Pier Paolo Pandolfi
Journal:  Sci Signal       Date:  2009-01-27       Impact factor: 8.192

Review 5.  The PI3K pathway as drug target in human cancer.

Authors:  Kevin D Courtney; Ryan B Corcoran; Jeffrey A Engelman
Journal:  J Clin Oncol       Date:  2010-01-19       Impact factor: 44.544

6.  From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells.

Authors:  S Yeh; H K Lin; H Y Kang; T H Thin; M F Lin; C Chang
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-11       Impact factor: 11.205

Review 7.  Targeting the phosphoinositide 3-kinase pathway in cancer.

Authors:  Pixu Liu; Hailing Cheng; Thomas M Roberts; Jean J Zhao
Journal:  Nat Rev Drug Discov       Date:  2009-08       Impact factor: 84.694

8.  FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt.

Authors:  Huadong Pei; Liang Li; Brooke L Fridley; Gregory D Jenkins; Krishna R Kalari; Wilma Lingle; Gloria Petersen; Zhenkun Lou; Liewei Wang
Journal:  Cancer Cell       Date:  2009-09-08       Impact factor: 31.743

9.  Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer.

Authors:  A H M Reid; G Attard; L Ambroisine; G Fisher; G Kovacs; D Brewer; J Clark; P Flohr; S Edwards; D M Berney; C S Foster; A Fletcher; W L Gerald; H Møller; V E Reuter; P T Scardino; J Cuzick; J S de Bono; C S Cooper
Journal:  Br J Cancer       Date:  2010-01-26       Impact factor: 7.640

10.  Multiple oncogenic pathway signatures show coordinate expression patterns in human prostate tumors.

Authors:  Chad J Creighton
Journal:  PLoS One       Date:  2008-03-19       Impact factor: 3.240

View more
  559 in total

1.  Small-molecule protein tyrosine kinase inhibitors for the treatment of metastatic prostate cancer.

Authors:  Gary E Gallick; Paul G Corn; Amado J Zurita; Sue-Hwa Lin
Journal:  Future Med Chem       Date:  2012-01       Impact factor: 3.808

2.  Pleckstrin homology domain leucine-rich repeat protein phosphatase (PHLPP): a new player in cell signaling.

Authors:  Noel A Warfel; Alexandra C Newton
Journal:  J Biol Chem       Date:  2011-12-05       Impact factor: 5.157

Review 3.  Prostate cancer in 2011: redefining the therapeutic landscape for CRPC.

Authors:  Carmel Pezaro; Gerhardt Attard
Journal:  Nat Rev Urol       Date:  2012-01-17       Impact factor: 14.432

4.  Suppression of survival signalling pathways by the phosphatase PHLPP.

Authors:  Audrey K O'Neill; Matthew J Niederst; Alexandra C Newton
Journal:  FEBS J       Date:  2012-03-16       Impact factor: 5.542

Review 5.  Therapeutic options for advanced prostate cancer: 2011 update.

Authors:  Aurelius Omlin; Johann S de Bono
Journal:  Curr Urol Rep       Date:  2012-04       Impact factor: 3.092

6.  Targeted androgen pathway suppression in localized prostate cancer: a pilot study.

Authors:  Elahe A Mostaghel; Peter S Nelson; Paul Lange; Daniel W Lin; Mary Ellen Taplin; Steven Balk; William Ellis; Philip Kantoff; Brett Marck; Daniel Tamae; Alvin M Matsumoto; Lawrence D True; Robert Vessella; Trevor Penning; Rachel Hunter Merrill; Roman Gulati; Bruce Montgomery
Journal:  J Clin Oncol       Date:  2013-12-09       Impact factor: 44.544

Review 7.  Molecular pathology of prostate cancer revealed by next-generation sequencing: opportunities for genome-based personalized therapy.

Authors:  Jiaoti Huang; Jason K Wang; Yin Sun
Journal:  Curr Opin Urol       Date:  2013-05       Impact factor: 2.309

8.  Crosstalk between nuclear MET and SOX9/β-catenin correlates with castration-resistant prostate cancer.

Authors:  Yingqiu Xie; Wenfu Lu; Shenji Liu; Qing Yang; Brett S Carver; Estelle Li; Yuzhuo Wang; Ladan Fazli; Martin Gleave; Zhenbang Chen
Journal:  Mol Endocrinol       Date:  2014-08-06

9.  Evidence of mTOR Activation by an AKT-Independent Mechanism Provides Support for the Combined Treatment of PTEN-Deficient Prostate Tumors with mTOR and AKT Inhibitors.

Authors:  Weisheng Zhang; Brian B Haines; Clay Efferson; Joe Zhu; Chris Ware; Kaiko Kunii; Jennifer Tammam; Minilik Angagaw; Marlene C Hinton; Heike Keilhack; Cloud P Paweletz; Theresa Zhang; Chris Winter; Sriram Sathyanarayanan; Jonathan Cheng; Leigh Zawel; Stephen Fawell; Gary Gilliland; Pradip K Majumder
Journal:  Transl Oncol       Date:  2012-12-01       Impact factor: 4.243

Review 10.  Novel therapies for the treatment of advanced prostate cancer.

Authors:  J M Clarke; A J Armstrong
Journal:  Curr Treat Options Oncol       Date:  2013-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.